NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
Clinical Trials
9 trialsNCT06686108 2025-05-07
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT05816746 2023-05-09
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Phase 2 Unknown
NCT05137886 2021-12-17
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT01483690 2020-10-27
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT03250962 2019-04-01
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT02264873 2018-10-15
Phase I, Dose Escalation Study of Decitabine
University of Florida
Phase 1 Completed
NCT00349596 2014-10-15
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 1 Completed